PYXS

NASDAQ open

Pyxis Oncology

1.82 USD
▲+0.14+8.04%
盘后 1.57 0.00%
2026-11-20
市值
$216.49M
市盈率
—
EPS
-1.27
股息率
—
52 周区间
1.03 – 5.55
成交量
2.58M
Beta
1.41
目标价
8.22
52W 低 1.0352W 高 5.55
价格走势

公司简介

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-o...